Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD45 and CAMPATH-1H Conditioning Regimen for Allogeneic Stem Cell Transplantation in Inherited Metabolic Storage Diseases
NCT00056979Phase 2Terminated
- Sponsor
- Baylor College of Medicine
- Start
- Jun 2002
- Primary completion
- Jun 2003
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of YTH25.4 + YTH54.12, alemtuzumab in Inherited metabolic storage disease (IMSD), sponsored by Baylor College of Medicine. Started Jun 2002; status: terminated.
02
Drugs
YTH25.4 + YTH54.12alemtuzumab
03
Conditions
Inherited metabolic storage disease (IMSD)
Beyond the preview
Go deeper on NCT00056979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00056979.